Morgan Stanley’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Morgan Stanley’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-500	Closed	–	–	6699
2016 Q3	$0	Hold	500	–	–	﹤0.01%	6641
2016 Q2	$0	Hold	500	–	–	﹤0.01%	6843
2016 Q1	$0	Sell	500 -1,200	-71%	-$494	﹤0.01%	6886
2015 Q4	$1K	Sell	1,700 -870	-34%	-$412	﹤0.01%	6611
2015 Q3	$2K	Sell	2,570 -930	-27%	-$477	﹤0.01%	6510
2015 Q2	$2K	Hold	3,500	–	–	﹤0.01%	6536
2015 Q1	$3K	Sell	3,500 -1,320	-27%	-$1.09K	﹤0.01%	6413
2014 Q4	$4K	Sell	4,820 -700	-13%	-$640	﹤0.01%	6378
2014 Q3	$5K	Hold	5,520	–	–	﹤0.01%	6343
2014 Q2	$5K	Buy	+5,520	New	+$6.62K	﹤0.01%	6301

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Morgan Stanley's PVCT Position: Q4 2016 in Review

Morgan Stanley sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 500 shares.

Morgan Stanley first reported a position in PVCT in Q2 2014 and held it in 10 quarters. The position peaked at $5K in Q3 2014. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

Morgan Stanley reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
Morgan Stanley sold 500 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016.
Morgan Stanley first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 10 quarters.
Morgan Stanley's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $5K in Q3 2014.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Morgan Stanley's 13F filing for Q4 2016, filed 13 Feb 2017.